InvestorsHub Logo
Followers 35
Posts 7957
Boards Moderated 1
Alias Born 04/04/2020

Re: caddiedad post# 437186

Saturday, 07/05/2025 11:00:13 AM

Saturday, July 05, 2025 11:00:13 AM

Post# of 437310
Caddiedad, Read the third paragraph under opinion. #2 you referenced is the case against Hikma. Using the argument of significant overlapping indications is how they invalidated the skinny label in GSK v Teva. That's how I expect this case to force the other generic companies out of the market. Same team, same playbook.
Sleven,
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News